"600% Momentum-Strategie": Aktien hebeln und Gewinne maximieren - sichern Sie sich jetzt das Kennenlernangebot für nur 39 Euro (statt 69 Euro) im Monat!

Alk-Abello A-S Bearer and-or registered B Aktie

NeuKaufen Kaufen Verkaufen Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

19,08 EUR +0,57 EUR +3,08 %

08:18:05

FSE

141,00 DKK +2,20 DKK +1,59 %

01.04.2025

CPH

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.4,12 Mrd. EUR

KGV43,20Div. Rendite0,00%

WKNA3DHX9

ISINDK0061802139

SymbolAKBLF

Alk-Abello A-S Bearer and-or registered B Aktien News

Sortieren:Datum Meistgelesen

05.02.24GlobeNewswireALK’s 2030 CO2 reduction targets have been approved by SBTi

31.01.24GlobeNewswireRelease date of annual report 2023 for ALK and webcast

25.01.24GlobeNewswireALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review

18.01.24GlobeNewswireALK completes first part of phase 1 trial with peanut SLIT-tablet

04.01.24GlobeNewswireALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy

04.01.24PR NewswireALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin Allergy

20.12.23GlobeNewswireALK – Financial calendar for the 2024 financial year

12.12.23GlobeNewswireALK expands partnership with Torii in Japan

15.11.23GlobeNewswireNine-month interim report (Q3) 2023

09.11.23GlobeNewswireRelease date of nine-month interim report (Q3) 2023 for ALK and audio cast

11.10.23GlobeNewswireLarge Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children

24.08.23GlobeNewswireSix-month interim report (Q2) 2023

18.08.23GlobeNewswireRelease date of six-month interim report (Q2) 2023 for ALK and audio cast

19.06.23GlobeNewswirePresident & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor

08.06.23GlobeNewswireLarge Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s house dust mite tablet in young children

09.05.23GlobeNewswireThree-month interim report (Q1) 2023

01.05.23GlobeNewswireRelease date of three-month interim report (Q1) 2023 for ALK and audio cast

17.04.23GlobeNewswireALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook

31.03.23GlobeNewswireGrant of share-based long-term incentive instruments to members of the Board of Management and key employees

23.03.23GlobeNewswireAnnual General Meeting in ALK-Abelló A/S held on 23 March 2023

02.03.23GlobeNewswireReport on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

27.02.23GlobeNewswireAnnual General Meeting in ALK on 23 March 2023

10.02.23GlobeNewswireALK appoints Claus Steensen Sølje as new Chief Financial Officer (CFO)

08.02.23GlobeNewswireReport on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

25.01.23PR NewswireU.S. FDA Approves ALK's ODACTRA® (House Dust Mite Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Adolescents

Alk-Abello A-S Bearer and-or registered B News

Alk-Abello A-S Bearer and-or registered B News: auf dieser Seite finden Sie alle Alk-Abello A-S Bearer and-or registered B News und Nachrichten zur Alk-Abello A-S Bearer and-or registered B Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Alk-Abello A-S Bearer and-or registered B News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Alk-Abello A-S Bearer and-or registered B News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.